Publications

publications by categories in reversed chronological order.

2022

  1. Optimized high-throughput screening of non-coding variants identified from genome-wide association studies
    Tunc Morova, Yi Ding, Chia-Chi F Huang, Funda Sar, Tommer Schwarz, Claudia Giambartolomei, Sylvan C Baca, Dennis Grishin, Faraz Hach, Alexander Gusev, Matthew L Freedman, Bogdan Pasaniuc, and Nathan A Lack
    Nucleic Acids Research, Dec 2022
  2. Dynamic phase separation of the androgen receptor and its coactivators key to regulate gene expression
    Fan Zhang, Maitree Biswas, Shabnam Massah, Joseph Lee, Shreyas Lingadahalli, Samantha Wong, Christopher Wells, Jane Foo, Nabeel Khan, Helene Morin, Neetu Saxena, Sonia H Y Kung, Bei Sun, Ana Karla Parra Nuñez, Christophe Sanchez, Novia Chan, Lauren Ung, Umut Berkay Altintas, Jennifer M Bui, Yuzhuo Wang, Ladan Fazli, Htoo Zarni Oo, Paul S Rennie, Nathan A. Lack, Artem Cherkasov, Martin E Gleave, Jörg Gsponer, and Nada Lallous
    Nucleic Acids Research, Dec 2022
  3. Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential
    Jeroen Kneppers, Tesa M. Severson, Joseph C. Siefert, Pieter Schol, Stacey E. P. Joosten, Ivan Pak Lok Yu, Chia-Chi Flora HuangTunc MorovaUmut Berkay Altintas, Claudia Giambartolomei, Ji-Heui Seo, Sylvan C. Baca, Isa Carneiro, Eldon Emberly, Bogdan Pasaniuc, Carmen Jerónimo, Rui Henrique, Matthew L. Freedman, Lodewyk F. A. Wessels, Nathan A. Lack, Andries M. Bergman, and Wilbert Zwart
    Nature Communications, Nov 2022
  4. Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation
    Sylvan C. Baca, Cassandra Singler, Soumya Zacharia, Ji-Heui Seo, Tunc Morova, Faraz Hach, Yi Ding, Tommer Schwarz, Chia-Chi Flora Huang, Jacob Anderson, André P. Fay, Cynthia Kalita, Stefan Groha, Mark M. Pomerantz, Victoria Wang, Simon Linder, Christopher J. Sweeney, Wilbert Zwart, Nathan A. Lack, Bogdan Pasaniuc, David Y. Takeda, Alexander Gusev, and Matthew L. Freedman
    Nature Genetics, Sep 2022
  5. EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities
    Ozlem Yedier-Bayram, Bengul Gokbayrak, Alisan Kayabolen, Ali Cenk Aksu, Ayse Derya Cavga, Ahmet Cingöz, Ezgi Yagmur Kala, Goktug Karabiyik, Rauf Günsay, Beril Esin, Tunc MorovaFirat Uyulur, Hamzah Syed, Martin Philpott, Adam P. Cribbs, Sonia H. Y. Kung, Nathan A. Lack, Tamer T. Onder, and Tugba Bagci-Onder
    Cell Death & Disease, Aug 2022
  6. Epigenetic-focused CRISPR/Cas9 screen identifies ASH2L as a regulator of glioblastoma cell survival
    Ezgi Ozyerli-Goknar, Ezgi Yagmur Kala, Ali Cenk Aksu, Ipek Bulut, Ahmet Cingöz, Sheikh Nizamuddin, Martin Biniossek, Fidan Seker-Polat, Tunc Morova, Can Aztekin, Sonia H.A. Kung, Hamzah Syed, Nurcan Tuncbag, Mehmet Gonen, Martin Philpott, Adam P. Cribbs, Ceyda Acilan, Nathan A. Lack, Tamer T. Onder, H.T. Marc Timmers, and Tugba Bagci-Onder
    bioRxiv, Aug 2022
  7. Protein Scaffold-Based Multimerization of Soluble ACE2 Efficiently Blocks SARS-CoV-2 Infection In Vitro and In Vivo
    Alisan Kayabolen, Ugur Akcan, Dogancan Ozturan, Hivda Ulbegi-Polat, Gizem Nur Sahin, Nareg Pinarbasi-Degirmenci, Canan Bayraktar, Gizem Soyler, Ehsan Sarayloo, Elif Nurtop, Berna Ozer, Gulen Guney-Esken, Tayfun Barlas, Ismail Selim Yildirim, Ozlem Dogan, Sercin Karahuseyinoglu, Nathan A. Lack, Mehmet Kaya, Cem Albayrak, Fusun Can, Ihsan Solaroglu, and Tugba Bagci-Onder
    Advanced Science, Jul 2022
  8. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer
    Cameron Herberts, Matti Annala, Joonatan Sipola, Sarah W. S. Ng, Xinyi E. Chen, Anssi Nurminen, Olga V. Korhonen, Aslı D. Munzur, Kevin Beja, Elena Schönlau, Cecily Q. Bernales, Elie Ritch, Jack V. W. Bacon, Nathan A. Lack, Matti Nykter, Rahul Aggarwal, Eric J. Small, Martin E. Gleave, David A. Quigley, Felix Y. Feng, Kim N. Chi, and Alexander W. Wyatt and
    Nature, Jul 2022
  9. Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence
    Simon Linder, Marlous Hoogstraat, Suzan Stelloo, Nils Eickhoff, Karianne Schuurman, Hilda Barros, Maartje Alkemade, Elise M. Bekers, Tesa M. Severson, Joyce Sanders, Chia-Chi Flora HuangTunc MorovaUmut Berkay Altintas, Liesbeth Hoekman, Yongsoo Kim, Sylvan C. Baca, Martin Sjöström, Anniek Zaalberg, Dorine C. Hintzen, Jeroen Jong, Roelof J.C. Kluin, Iris Rink, Claudia Giambartolomei, Ji-Heui Seo, Bogdan Pasaniuc, Maarten Altelaar, René H. Medema, Felix Y. Feng, Amina Zoubeidi, Matthew L. Freedman, Lodewyk F.A. Wessels, Lisa M. Butler, Nathan A. Lack, Henk Poel, Andries M. Bergman, and Wilbert Zwart
    Cancer Discovery, Jun 2022
  10. Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasis
    Yun Zhang, Joana Liu Donaher, Sunny Das, Xin Li, Ferenc Reinhardt, Jordan A. Krall, Arthur W. Lambert, Prathapan Thiru, Heather R. Keys, Mehreen Khan, Matan Hofree, Molly M. Wilson, Ozlem Yedier-Bayram, Nathan A. Lack, Tamer T. Onder, Tugba Bagci-Onder, Michael Tyler, Itay Tirosh, Aviv Regev, Jacqueline A. Lees, and Robert A. Weinberg
    Nature Cell Biology, Apr 2022
  11. Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer
    Adrianna A. Mendes, Jiayun Lu, Harsimar B. Kaur, Siqun L. Zheng, Jianfeng Xu, Jessica Hicks, Adam B. Weiner, Edward M. Schaeffer, Ashley E. Ross, Steven P. Balk, Mary-Ellen Taplin, Nathan A. LackEmirhan Tekoglu, Janielle P. Maynard, Angelo M. De Marzo, Emmanuel S. Antonarakis, Karen S. Sfanos, Corinne E. Joshu, Eugene Shenderov, and Tamara L. Lotan
    Cancer, Mar 2022
  12. Androgen Receptor-Mediated Transcription in Prostate Cancer
    Dogancan OzturanTunc Morova, and Nathan A. Lack
    Cells, Mar 2022

2021

  1. Histologically benign PI-RADS 4 and 5 lesions contain cancer-associated epigenetic alterations
    Ceren Seref,  Acar, Mert Kılıç, Metin Vural, Yeşim Sağlıcan, Hilal Saraç, Bilgen Coşkun,  İnce, Tarık Esen, and Nathan A. Lack
    The Prostate, Oct 2021
  2. Development of 2-(5, 6, 7-Trifluoro-1H-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer
    Eric Leblanc, Fuqiang Ban, Ayse Derya Cavga, Sam Lawn, Chia-Chi Flora Huang, Sankar Mohan, Matthew E. K. Chang, Mark R. Flory, Fariba Ghaidi, Shreyas Lingadahalli, Gang Chen, Ivan Pak Lok Yu, Hélène Morin, Nada Lallous, Martin E. Gleave, Hisham Mohammed, Robert N. Young, Paul S. Rennie, Nathan A. Lack, and Artem Cherkasov
    Journal of Medicinal Chemistry, Oct 2021
  3. DNA binding alters ARv7 dimer interactions
    Fatma OzgunZeynep KayaTunc Morova, Bart Geverts, Tsion E. Abraham, Adriaan B. Houtsmuller, Martin E. Royen, and Nathan A. Lack
    Journal of Cell Science, Jul 2021
  4. Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer
    Fuqiang Ban, Eric Leblanc, Ayse Derya CavgaChia-Chi Flora Huang, Mark R. Flory, Fan Zhang, Matthew E. K. Chang, Hélène Morin, Nada Lallous, Kriti Singh, Martin E. Gleave, Hisham Mohammed, Paul S. Rennie, Nathan A. Lack, and Artem Cherkasov
    Cancers, Jul 2021
  5. Functional mapping of androgen receptor enhancer activity
    Chia-Chi Flora HuangShreyas LingadahalliTunc MorovaDogancan Ozturan, Eugene Hu, Ivan Pak Lok Yu, Simon Linder, Marlous Hoogstraat, Suzan Stelloo, Funda Sar, Henk Poel, Umut Berkay Altintas, Mohammadali Saffarzadeh, Stephane Le Bihan, Brian McConeghy, Bengul Gokbayrak, Felix Y. Feng, Martin E. Gleave, Andries M. Bergman, Colin Collins, Faraz Hach, Wilbert Zwart, Eldon Emberly, and Nathan A. Lack
    Genome Biology, May 2021

2020

  1. Androgen receptor-binding sites are highly mutated in prostate cancer
    Tunc Morova, Daniel R. McNeill, Nada Lallous, Mehmet Gönen, Kush Dalal, David M. Wilson, Attila Gürsoy,  Keskin, and Nathan A. Lack
    Nature Communications, Feb 2020

2019

  1. DeepCOP: deep learning-based approach to predict gene regulating effects of small molecules
    Godwin Woo, Michael Fernandez, Michael Hsing, Nathan A LackAyse Derya Cavga, and Artem Cherkasov
    Bioinformatics, Aug 2019
  2. Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer
    Hilal SaracTunc Morova, Elisabete Pires, James McCullagh, Anıl Kaplan, Ahmet Cingöz, Tugba Bagci-Onder, Tamer Önder, Akane Kawamura, and Nathan A. Lack
    Oncogene, Dec 2019
  3. Androgen receptor plasticity and its implications for prostate cancer therapy
    Oliver Snow, Nada Lallous, Kriti Singh, Nathan Lack, Paul Rennie, and Artem Cherkasov
    Cancer Treatment Reviews, Dec 2019
  4. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer
    Laura Cato, Jonas Tribolet-Hardy, Irene Lee, Jaice T. Rottenberg, Ilsa Coleman, Diana Melchers, René Houtman, Tengfei Xiao, Wei Li, Takuma Uo, Shihua Sun, Nane C. Kuznik, Bettina Göppert, Fatma Ozgun, Martin E. Royen, Adriaan B. Houtsmuller, Raga Vadhi, Prakash K. Rao, Lewyn Li, Steven P. Balk, Robert B. Den, Bruce J. Trock, R. Jeffrey Karnes, Robert B. Jenkins, Eric A. Klein, Elai Davicioni, Friederike J. Gruhl, Henry W. Long, X. Shirley Liu, Andrew C.B. Cato, Nathan A. Lack, Peter S. Nelson, Stephen R. Plymate, Anna C. Groner, and Myles Brown
    Cancer Cell, Mar 2019

2018

  1. Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor
    Kush Dalal, Helene Morin, Fuqiang Ban, Ashley Shepherd, Michael Fernandez, Kevin J. Tam, Huifang Li, Eric LeBlanc, Nathan Lack, Helge Prinz, Paul S. Rennie, and Artem Cherkasov
    European Journal of Medicinal Chemistry, Sep 2018
  2. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
    David A. Quigley, Ha X. Dang, Shuang G. Zhao, Paul Lloyd, Rahul Aggarwal, Joshi J. Alumkal, Adam Foye, Vishal Kothari, Marc D. Perry, Adina M. Bailey, Denise Playdle, Travis J. Barnard, Li Zhang, Jin Zhang, Jack F. Youngren, Marcin P. Cieslik, Abhijit Parolia, Tomasz M. Beer, George Thomas, Kim N. Chi, Martin Gleave, Nathan A. Lack, Amina Zoubeidi, Robert E. Reiter, Matthew B. Rettig, Owen Witte, Charles J. Ryan, Lawrence Fong, Won Kim, Terence Friedlander, Jonathan Chou, Haolong Li, Rajdeep Das, Hui Li, Ruhollah Moussavi-Baygi, Hani Goodarzi, Luke A. Gilbert, Primo N. Lara, Christopher P. Evans, Theodore C. Goldstein, Joshua M. Stuart, Scott A. Tomlins, Daniel E. Spratt, R. Keira Cheetham, Donavan T. Cheng, Kyle Farh, Julian S. Gehring, Jörg Hakenberg, Arnold Liao, Philip G. Febbo, John Shon, Brad Sickler, Serafim Batzoglou, Karen E. Knudsen, Housheng H. He, Jiaoti Huang, Alexander W. Wyatt, Scott M. Dehm, Alan Ashworth, Arul M. Chinnaiyan, Christopher A. Maher, Eric J. Small, and Felix Y. Feng
    Cell, Jul 2018
  3. Impact of the ST101 clone on fatality among patients with colistin-resistant Klebsiella pneumoniae infection
    Fusun Can, Sirin Menekse, Pelin Ispir, Nazlı Atac, Ozgur Albayrak, Tuana Demir, Doruk Can Karaaslan, Salih Nafiz Karahan, Mahir Kapmaz, Ozlem Kurt Azap, Funda Timurkaynak, Serap Simsek Yavuz, Seniha Basaran, Fugen Yoruk, Alpay Azap, Safiye Koculu, Nur Benzonana, Nathan A Lack, Mehmet Gönen, and Onder Ergonul
    Journal of Antimicrobial Chemotherapy, Feb 2018

2017

  1. KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL
    Ibrahim Cagri Kurt, Ilknur Sur, Ezgi Kaya, Ahmet Cingoz, Selena Kazancioglu, Zeynep Kahya, Omer Duhan Toparlak, Filiz Senbabaoglu, Zeynep Kaya, Ezgi Ozyerli, Sercin Karahüseyinoglu, Nathan A Lack, Zeynep H Gümüs, Tamer T Onder, and Tugba Bagci-Onder
    Cell Death & Disease, Jun 2017
  2. Investigation of the mycobacterial enzyme HsaD as a potential novel target for anti-tubercular agents using a fragment-based drug design approach
    Ali Ryan, Elena Polycarpou, Nathan A Lack, Dimitrios Evangelopoulos, Christian Sieg, Alice Halman, Sanjib Bhakta, Olga Eleftheriadou, Timothy D McHugh, Sebastian Keany, Edward D Lowe, Romain Ballet, Areej Abuhammad, William R Jacobs, Alessio Ciulli, and Edith Sim
    British Journal of Pharmacology, May 2017
  3. Pathogenic mycobacteria achieve cellular persistence by inhibiting the Niemann-Pick Type C disease cellular pathway
    Paul Fineran, Emyr Lloyd-Evans, Nathan A. Lack, Nick Platt, Lianne C. Davis, Anthony J. Morgan, Doris Höglinger, Raju Venkata V. Tatituri, Simon Clark, Ian M. Williams, Patricia Tynan, Nada Al Eisa, Evgeniya Nazarova, Ann Williams, Antony Galione, Daniel S. Ory, Gurdyal S. Besra, David G. Russell, Michael B. Brenner, Edith Sim, and Frances M. Platt
    Wellcome Open Research, Jun 2017

2016

  1. Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme
    Filiz Senbabaoglu, Ahmet Cingoz, Ezgi Kaya, Selena Kazancioglu, Nathan A. Lack, Ceyda Acilan, and Tugba Bagci-Onder
    Cancer Biology & Therapy, Mar 2016
  2. Cytotoxicity and mitogenicity assays with real-time and label-free monitoring of human granulosa cells with an impedance-based signal processing technology intergrating micro-electronics and cell biology
    Ozgur Oktem, Gamze Bildik, Filiz Senbabaoglu, Nathan A. Lack, Nazli Akin, Feridun Yakar, Defne Urman, Yilmaz Guzel, Basak Balaban, Akira Iwase, and Bulent Urman
    Reproductive Toxicology, Apr 2016

2015

  1. Determining the origin of synchronous multifocal bladder cancer by exome sequencing
    Omer Acar, Ezgi Özkurt, Gulfem Demir, Hilal Sarac, Can Alkan, Tarık Esen, Mehmet Somel, and Nathan A. Lack
    BMC Cancer, Nov 2015
  2. Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells
    Can Küçük, Bei Jiang, Xiaozhou Hu, Wenyan Zhang, John K. C. Chan, Wenming Xiao, Nathan Lack, Can Alkan, John C. Williams, Kendra N. Avery, Pınar Kavak, Anna Scuto, Emel Sen, Philippe Gaulard, Lou Staudt, Javeed Iqbal, Weiwei Zhang, Adam Cornish, Qiang Gong, Qunpei Yang, Hong Sun, Francesco d’Amore, Sirpa Leppä, Weiping Liu, Kai Fu, Laurence Leval, Timothy McKeithan, and Wing C. Chan
    Nature Communications, Jan 2015

2014

  1. Characterisation of a putative AraC transcriptional regulator from Mycobacterium smegmatis
    Dimitrios Evangelopoulos, Antima Gupta, Nathan A. Lack, Arundhati Maitra, Annemieke M.C. Bokum, Sharon Kendall, Edith Sim, and Sanjib Bhakta
    Tuberculosis, Dec 2014
  2. Deletion of conserved protein phosphatases reverses defects associated with mitochondrial DNA damage in Saccharomyces cerevisiae
    Görkem Garipler, Nebibe Mutlu, Nathan A. Lack, and Cory D. Dunn
    Proceedings of the National Academy of Sciences, Jan 2014

2013

  1. Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
    Huifang Li, Mohamed D.H. Hassona, Nathan A. Lack, Peter Axerio-Cilies, Eric Leblanc, Peyman Tavassoli, Natalia Kanaan, Kate Frewin, Kriti Singh, Hans Adomat, Konrad J. Böhm, Helge Prinz, Emma Tomlinson Guns, Paul S. Rennie, and Artem Cherkasov
    Molecular Cancer Therapeutics, Nov 2013
  2. New Therapeutics to Treat Castrate-Resistant Prostate Cancer
    Omer Acar, Tarık Esen, and Nathan A. Lack
    The Scientific World Journal, Nov 2013
  3. Genetic variants of MARCO are associated with susceptibility to pulmonary tuberculosis in a Gambian population
    Dawn ME Bowdish, Kaori Sakamoto, Nathan A Lack, Philip C Hill, Giorgio Sirugo, Melanie J Newport, Siamon Gordon, Adrian VS Hill, and Fredrick O Vannberg
    BMC Medical Genetics, Apr 2013
  4. Targeting the Binding Function 3 (BF3) Site of the Androgen Receptor Through Virtual Screening. 2. Development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole Derivatives
    Ravi Shashi Nayana Munuganti, Eric Leblanc, Peter Axerio-Cilies, Christophe Labriere, Kate Frewin, Kriti Singh, Mohamed D. H. Hassona, Nathan A. Lack, Huifang Li, Fuqiang Ban, Emma Tomlinson Guns, Robert Young, Paul S. Rennie, and Artem Cherkasov
    Journal of Medicinal Chemistry, Jan 2013